Ora has brought on industry expert Paul Colvin as its new chief operating officer to help lead the ophthalmology CRO’s global growth.
Colvin brings more than 30 years experience in the industry with a 14-year stint at Eli Lilly and 12 years leading PPD’s clinical development business, the company said in an April 6 press release. More recently, he held the positions of president of clinical development solutions and chief business officer at Syneos Health. Colvin started his career as a pharmacist.
At Ora, Colvin will report directly to CEO Stuart Abelson.
Andover, Massachusetts-based Ora focuses on ophthalmic treatments for dry eye and glaucoma, allergy, medical devices, anti-infective and anti-inflammatories.
In November, the company inked a deal with the U.K. nonprofit Macular Society to continue to support the advancement of new treatment options in eye care across Great Britain.